Opinion|Videos|August 28, 2024
Examining Trial Data on Omaveloxolone Efficacy
A physician examines clinical trial results that impact their approach to treating patients with Friedreich ataxia.
Advertisement
Episodes in this series
- In 2023, a propensity matched comparison of MOXIe extension patients to an untreated cohort found a significant slowing of disease progression per mFARS of 3.0 points compared to 6.6 points, respectively. Are these results clinically meaningful for patients and how does this relate to your everyday clinical practice?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
2
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
3
Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI
4
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
5